

**Design, synthesis and biological evaluation of small  
molecule agonist of the Glucagon-Like Peptide-1 Receptor  
(GLP-1R) as an anti-diabetic agent**

**A**

**Thesis**

For the Award of the Degree of

**DOCTOR OF PHILOSOPHY**

**In**

**Science**

Submitted

By

**Khyati (Roll No.-D15016)**

*Under the supervision of*

**Dr. Prosenjit Mondal**

**(Assistant Professor)**



**School of Basic Sciences**

**Indian Institute of Technology Mandi**

**Mandi, Himachal Pradesh, India-175005**

## Declaration by the Research Scholar

---

I hereby declare that the entire work embodied in the thesis “Design, synthesis and biological evaluation of small molecule agonist of the Glucagon-Like Peptide-1Receptor (GLP-1R) as an antidiabetic agent” is the result of investigations carried out by me in the School of Basic Sciences, Indian Institute of Technology Mandi, under the supervision of Dr. Prosenjit Mondal, and that it has not been submitted elsewhere for any degree or diploma. In keeping with the general practice, due acknowledgements have been made wherever the work described is based on the finding of other investigators.

**Place:** Kamand, Mandi, (H.P), India.

**Signature:**

**Date:**

**Name:** Khyati

## Declaration by the Research Advisor

---

---

I hereby certify that the entire work in this Thesis has been carried out by **Khyati (Roll No.-D15016)**, under my supervision in the **School of Basic Sciences**, Indian Institute of Technology Mandi, and that no part of it has been submitted elsewhere for any Degree or Diploma.

**Signature:**

**Name of the Guide:** Dr. Prosenjit Mondal

**Date:**

Dedicated to...

*“My Beloved Family*

and

*Animal Life Sacrificed”*

## ACKNOWLEDGEMENT

---

*“There are times when silence speaks so much more loudly than words of praise to only as good as belittle a person, whose words do not express, but only put a veneer over true feelings, which are of gratitude at this point of time”.*

Every project, big or small, is thriving mainly due to the effort of several people valuable advice or a helping hand. I sincerely appreciate the inspiration; support, and guidance of all those people who have been instrumental in making this project a success. No job or task can be completed without the co-operation and support of people around us. This work owes its existence to all those who have helped or somehow associated with it.

Firstly, I feel deeply honored in expressing my sincere thanks to my supervisor Dr. Prosenjit Mondal, Assistant professor, School of Basic Sciences, Indian Institute of Technology Mandi, Himachal Pradesh, India, for his supervision, humanity, kind attitude, inspiration and guidance towards me and my project. I am thankful to UGC for fellowship support during my tenure.

I owe a profound sense of gratitude and appreciation to our collaborators, Dr. Subrata Ghosh for guidance and providing me with chemistry lab facility, Dr. Debabrata Ghosh for the animal facility in IITR Lucknow and Dr. Rakesh Kundu for the animal facility in Visva Bharati University, Santiniketan, West Bengal.

I am grateful to all DC members (Dr. Subrata Ghosh, Dr. Subhajit Roy Chowdhery, Dr. Venkata Krishnan, Dr. Shyam Kumar Maskapalli, and Dr. Amit Jaiswal) for their suggestions and evaluation during my Ph.D.

I want to express my gratitude to the Director, IIT Mandi for his support and encouragements, especially, the research facilities at the Advanced Materials Research Centre (AMRC) and BIOX center, IIT Mandi.

I feel incredibly fortunate to have the support of Lab members, Aditya Kar, Abhinav Chobey, Surbhi Dogra, P. Vineeth Daniel, Prateep Singh Sagra, and Dr. Pankaj Gaur for their help in in vivo, in vitro and chemistry experiments. I feel honored in expressing my deep sense of gratitude to Dr. Budheswar Dehury and Dr. Sunil Kumar for simulation work.

I want to express everlasting gratitude to my friends, Ashish Ranjan, Maneesh Lingwan, Nagaraju Nakka, Anuj Sharma, Vikas Singh, Ruchi Gera, Amrita, Ashish Bahuguna, Navneet Singh, Saurav Sharma, Akhilesh Sharma, Diksha Thakur, Krishan, Gaurav Dey, Alpana, Snehasish, Deepak Kumar and Ashutosh Singh for their co-operation, providing eternal optimism and encouragement during my PhD.

At last and most importantly, I thank my parents and my sister, what I am today is just because of them. Words will be less to describe the support, encouragement, and unconditional love provided by my family.

**(Khyati)**

## PREFACE

---

Diabetes is a worldwide societal fiasco that pulverizes individual misery and has a high mortality rate across the globe. It is affecting individuals of all age groups, from children to individuals over 65 years of age. Diabetes mellitus is the condition of insufficient supply of insulin by  $\beta$ -cells or incapability of the body to use existing insulin (insulin resistant condition), thereby leading to hyperglycemia and eventually diabetes mellitus. The Glucagon-Like Peptide-1 (GLP-1), and GLP-1Receptor (GLP-1R) has been the focus of considerable research attention for their ability to reduce blood glucose level, body weight, protect  $\beta$ -cell mass and augmenting insulin secretion without causing hypoglycemia. Thus, GLP-1R has become a promising therapeutic target for the treatment of type 2 diabetes. However, GLP-1 is not available as therapeutics in the market, due to its very short half-life of 2 mins in the circulation. To overcome this limitation, researchers have introduced many stable analogs of GLP-1 such as Exendin-4 and Liraglutide.

Although available GLP-1 stable analogs like Exendin-4 and Liraglutide have more half-life than native GLP-1, they have several disadvantages like subcutaneous administration, belching, diarrhea, high cost, and low stability due to their peptidic nature. That represents an immense need of a small molecule GLP-1 analog as an anti-diabetic therapeutics. Thus, small-molecule agonists that target GLP-1R are preferable, but difficult to identify and develop, probably due to the large and open binding pocket of family B of G-protein-coupled receptors (GPCRs). This thesis work not only introduces a new strategy for the development of small-molecule agonist of GLP-1R but also presents the application of developed novel small molecule GLP-1R agonist in the treatment of diabetes.

# CONTENTS

---

Declaration by the Research Scholar .....	II
Declaration by the Research Advisor .....	III
ACKNOWLEDGEMENT .....	V
PREFACE .....	VII
List of Figures.....	XIII
List of Tables.....	XVI
ABBREVIATION.....	XVII
1. INTRODUCTION.....	1
1.1. Diabetes .....	1
1.2. Non-Alcoholic Fatty liver diseases, obesity, and Type 2 Diabetes.....	4
1.3. Incretin based therapies for the treatment of T2DM.....	7
1.4. Factors accountable for synthesis and secretion of GLP-1:.....	9
1.5. Physiological and pharmacological effects of GLP-1R agonists .....	12
1.5.1. The effect of GLP-1R agonists on body weight.....	12
1.5.2. Signaling of GLP-1 in pancreatic $\beta$ -cells. ....	12
1.5.3. GLP-1 signaling in Liver .....	14
1.6. The structure of GLP-1R:.....	15
1.7. The therapeutic potential of GLP-1 receptor agonists.....	17
1.7.1. Small-molecule agonists of the GLP-1R:.....	20
Aims and Objectives.....	25



Objectives of the Thesis: .....	26
Overview of the chapters: .....	27
2. Insights into the dynamics behavior of Glucagon-Like Peptide-1 Receptor (GLP-1R) with its small molecule agonists: An approach for screening of small molecule GLP-1R agonist.....	31
2.1. Introduction.....	31
2.2. Materials and Methods .....	33
2.2.1. Preparation of Protein Structure.....	33
2.2.2. Ligand selection and preparation .....	33
2.2.3. Molecular docking .....	34
2.2.4. Evaluation and visualization of docked conformations .....	34
2.2.5. Molecular Dynamics Simulation .....	34
2.2.6. MD Trajectory Analysis .....	36
2.2.7. Principal Component Analysis and Clustering.....	36
2.2.8. MM/PBSA Binding Free Energy .....	37
2.3. Results and Discussions.....	38
2.3.1. Molecular docking of small-molecule GLP-1R agonist:.....	38
2.3.2. Analysis of MD trajectory of GLP-1R complexes.....	44
2.3.3. Intermolecular H-bond and clustering analysis.....	47
2.3.4. Essential dynamics (ED) .....	48
2.3.5. Binding Free Energy Calculation.....	51
2.3.6. Intermolecular contact analysis before and after MD .....	54

2.3.7. Screening of small molecule agonist of GLP-1R by utilizing ecto-cellular domain: .....	61
2.4. Conclusion.....	74
3. Synthesis, and biological evaluation of indole quinoxaline derivatives as a beta-cell protecting drug ameliorates streptozotocin-induced diabetes .....	77
3.1. Introduction: .....	77
3.2.1. General details, Instruments, and Measurements: .....	79
3.2.2. Synthesis:.....	79
3.2.3. Characterisation data of (PK2-PK5): .....	83
3.2.4. Molecular dynamics simulations:.....	84
3.2.5. Cell Culture: .....	85
3.2.6. Cell Viability Assay:.....	86
3.2.7. Pharmacokinetics and tissue distribution of PK2:.....	86
3.2.8. Animals: .....	87
3.2.9. GLP-1R Internalization: .....	88
3.2.10. PKA activity Assay: .....	88
3.2.11. Western Blot:.....	88
3.2.12. Immunohistochemistry: .....	89
3.2.13. TUNEL assay: .....	90
3.2.14 TXNIP Promoter activity assay:.....	90
3.2.15. Quantification and Statistical Analysis:.....	90
3.3. Results and Discussion: .....	91

3.3.1. Synthesis of set of PK molecules: .....	91
3.3.2. Spectroscopic Data: .....	93
3.3.3. Internalization of GLP-1R: A ligand-binding assay: .....	101
3.3.4. Activation of PKA-CREB signaling: A validation of agonism .....	104
3.3.5. Dynamic stability of GLP-1R-PK2 complex .....	105
3.3.6. In vivo pharmacokinetics and tissue distribution study in mice:.....	112
3.3.7. PK2 protects against STZ induced pancreatic $\beta$ -cell apoptosis and dysfunction. ....	114
3.3.8. PK2 inhibit TXNIP expression in $\beta$ -cell.....	119
3.4. Discussion: .....	119
4. An indole quinoxaline derivative, PK2 alleviates hepatic steatosis by attenuating de-novo lipogenesis through the AMPK/ChREBP pathway.....	123
4.1. Introduction: .....	123
4.2. Material and Methods: .....	126
4.2.1. Cell Culture: .....	126
4.2.2. ORO Staining: .....	126
4.2.3. Animals: .....	126
4.2.4. Immunocytochemistry: .....	127
4.2.5. Western Blot:.....	127
4.2.6. Quantification and Statistical Analysis:.....	128
4.3. Results and Discussion: .....	128

4.3.1. Screening of PK set of compounds in reducing palmitate-induced neutral lipid accumulation in HepG2 cells: .....	128
4.3.2. PK2 treatment in diet-induced obese mice reduces fat accumulation, improves fasting blood glucose and insulin sensitivity .....	131
4.3.3. PK2 ameliorates HFD induced liver toxicity:.....	133
4.3.4. PK2 rescue HFD induced fatty liver pathologies through AMPK signaling axis:.....	135
4.3.5. PK2 improves hyperinsulinemia induce insulin resistance in HepG2 cells: .....	137
4.3.6. PK2 treatment restricts ChREBP shuttling to cytoplasm: .....	138
4.4. Discussion: .....	139
Conclusion and Future Scope: .....	144
References: .....	147
List of Publications: .....	168
Paper Communicated: .....	168
Patent: .....	169
List of Conferences/Workshop:.....	169
Re-print permission: .....	171